181 related articles for article (PubMed ID: 20655401)
1. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.
Becke S; Aue S; Thomas D; Schader S; Podlech J; Bopp T; Sedmak T; Wolfrum U; Plachter B; Reyda S
Vaccine; 2010 Aug; 28(38):6191-8. PubMed ID: 20655401
[TBL] [Abstract][Full Text] [Related]
2. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
4. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
5. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
6. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
7. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
[TBL] [Abstract][Full Text] [Related]
8. DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice.
Gallez-Hawkins G; Li X; Franck AE; Thao L; Lacey SF; Diamond DJ; Zaia JA
Vaccine; 2004 Dec; 23(6):819-26. PubMed ID: 15542207
[TBL] [Abstract][Full Text] [Related]
9. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
10. Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity.
Nguyen TH; Mifsud NA; Stewart LA; Rose MJ; Etto TL; Williamson NA; Purcell AW; Kotsimbos T; Schwarer AP
Protein Expr Purif; 2008 Sep; 61(1):22-30. PubMed ID: 18539483
[TBL] [Abstract][Full Text] [Related]
11. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
12. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
13. Progress made towards the development of a CMV peptide vaccine.
Paston SJ; Dodi IA; Madrigal JA
Hum Immunol; 2004 May; 65(5):544-9. PubMed ID: 15172455
[TBL] [Abstract][Full Text] [Related]
14. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
Lilleri D; Zelini P; Fornara C; Comolli G; Revello MG; Gerna G
Clin Immunol; 2009 Jun; 131(3):395-403. PubMed ID: 19268633
[TBL] [Abstract][Full Text] [Related]
16. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.
Gyulai Z; Endresz V; Burian K; Pincus S; Toldy J; Cox WI; Meric C; Plotkin S; Gönczöl E; Berencsi K
J Infect Dis; 2000 May; 181(5):1537-46. PubMed ID: 10823751
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
19. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles.
Pepperl-Klindworth S; Frankenberg N; Plachter B
J Clin Virol; 2002 Aug; 25 Suppl 2():S75-85. PubMed ID: 12361759
[TBL] [Abstract][Full Text] [Related]
20. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases.
Zhong J; Khanna R
J Clin Virol; 2009 Dec; 46 Suppl 4():S68-72. PubMed ID: 19646921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
